Fig. 4: LAMP5 inhibits the degradation of IRF4 protein via the autophagy-lysosome pathway. | Oncogene

Fig. 4: LAMP5 inhibits the degradation of IRF4 protein via the autophagy-lysosome pathway.

From: LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy

Fig. 4

A, B Time course of IRF4 protein in ARP-1 or IM-9 cells (shCtrl or shLAMP5) treated with 100 μM cycloheximide (CHX). C, D IRF4 protein levels in ARP-1 or IM-9 (shCtrl or shLAMP5) treated with 2.5 μM MG-132 or 2.5 μM leupeptin for 7 h. E, F Co-immunoprecipitation of IRF4 with p62 or Hsc70 in ARP-1 or IM-9 cells. G, H Co-immunoprecipitation of IRF4 with p62 in ARP-1 or IM-9 cells (shCtrl or shLAMP5). I LC3B-I/II and p62 protein levels in shCtrl or shLAMP5 myeloma cells. J, K Immunofluorescent staining of IM-9 cells (shCtrl or shLAMP5) with DAPI and antibodies against IRF4, LC3B, or p62. Scale bar, 5 μm. L Co-immunoprecipitation of lysates from IM-9 cells (shCtrl or shLAMP5) treated with or without 20 μM chloroquine (CQ) for 24 h. A–I, and L are representative of two independent experiments. J and L are representative of three independent experiments.

Back to article page